INMED PHARMACEUTICALS INC. Prepaid Expense and Other Assets, Current
INMED PHARMACEUTICALS INC. (INM) had Prepaid Expense and Other Assets, Current of $241.30 thousand as of 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-09-09
- 2026-06-30: Prepaid Expense and Other Assets, Current $241.30K.
- 2026-03-31: Prepaid Expense and Other Assets, Current $617.21K.
- 2025-12-31: Prepaid Expense and Other Assets, Current $660.28K.
- 2025-09-30: Prepaid Expense and Other Assets, Current $191.75K.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $241.30K S-4/A · filed 2026-09-09 | |
| 2026-03-31 | $617.21K S-4 · filed 2026-07-02 | |
| 2025-12-31 | $660.28K 10-Q · filed 2026-02-11 | |
| 2025-09-30 | $191.75K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $319.55K S-4/A · filed 2026-09-09 | $321.75K 10-K · filed 2025-09-23 |
| 2025-03-31 | $507.87K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $643.99K 10-Q · filed 2025-02-12 | |
| 2024-09-30 | $148.88K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $477.75K 10-K · filed 2025-09-23 | |
| 2023-12-31 | $1.11M 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $215.01K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $498.03K 10-K · filed 2024-09-30 | |
| 2023-03-31 | $695.20K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $826.93K 10-Q · filed 2023-02-17 | |
| 2022-09-30 | $356.67K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $797.23K 10-K · filed 2023-09-29 | |
| 2022-03-31 | $1.31M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $140.51K 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $322.35K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $956.76K 10-K · filed 2022-09-23 | |
| 2021-03-31 | $1.33M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $28.46K 10-Q · filed 2021-02-11 | |
| 2020-09-30 | $524.20K 10-Q · filed 2020-12-17 | |
| 2020-06-30 | $418.92K 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |